Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of Intravesical Ruvidar® in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") or Patients Who Are Intolerant to BCG Therapy ("Study II")

NCT03945162 is registered in ClinicalTrials.gov with Theralase® Technologies Inc. as lead sponsor.

NCT NCT03945162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03945162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of Intravesical Ruvidar® in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") or Patients Who Are Intolerant to BCG Therapy ("Study II")
Lead sponsor
Theralase® Technologies Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 30, 2019
Completion date
December 31, 2027
Enrollment
90 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer ("nmibc") unresponsive/intolerant to bcg